+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia



A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia



Journal of Pediatrics 139(6): 790-796



Hydroxyurea improves hematologic values and decreases vaso-occlusive complications in adults and children with sickle cell anemia (SCA), but has not been tested in infants before the onset of chronic organ dysfunction. We conducted a collaborative pilot trial of hydroxyurea in infants with SCA to assess its (1) feasibility of administration, (2) toxicity, (3) hematologic effects, and (4) effect on spleen function. Patients with hemoglobin (Hb) SS or Sbeta(0) thalassemia (n = 28, median age 15 months) received hydroxyurea for 2 years at 20 mg/kg/day. Hydroxyurea was temporarily discontinued for predefined toxicity. Seven patients exited the study early: five for noncompliance or refusal to continue, one for mild stroke, and one for fatal splenic sequestration. The predominant toxicity was transient neutropenia, which was usually associated with a viral-like illness. After 2 years of treatment, mean Hb level = 8.8 g/dL and Hb F = 20.3%, both higher than predicted age-specific levels. Radionuclide splenic uptake was absent in 47% of patients at study completion, compared with predicted functional asplenia in 80% of the patients. Hydroxyurea therapy for infants with SCA is feasible and well tolerated, has hematologic efficacy, and may delay functional asplenia. The potential for hydroxyurea to preserve organ function in SCA should be further evaluated.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010105814

Download citation: RISBibTeXText

PMID: 11743503

DOI: 10.1067/mpd.2001.119590


Related references

A two-year pilot trial of hydroxyurea in very young children with sickle cell disease. Blood 94(10 SUPPL 1 PART 1): 644a, Nov 15, 1999

A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatric Blood and Cancer 52(5): 609-615, 2008

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatric Hematology and Oncology 16(3): 221-232, 1999

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94(5): 1550-1554, 1999

Hydroxyurea in very young children with sickle cell anemia is not a cure-all. Journal of Pediatrics 139(6): 763-764, 2001

Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State. American Journal of Preventive Medicine 51(1 Suppl 1): S31-S38, 2018

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 132(4): 677-683, 2013

Efficacy of hydroxyurea to prevent organ damage in young children with sickle cell anemia. 2007

Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 94(5): 1550-1554, Sept 1, 1999

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine 332(20): 1317-1322, 1995

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 75(6): 300-326, 1996

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial. Pediatric Blood and Cancer 63(1): 98-104, 2016

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. American Journal of Hematology 64(1): 26-31, 2000

Safety and hematologic efficacy of four years of hydroxyurea therapy for very young children with sickle cell anemia The HUSOFT Extension Study. Blood 98(11 Part 1): 489a, November 16, 2001

A randomized, controlled pilot trial of a school intervention for children with sickle cell anemia. Journal of Pediatric Psychology 29(1): 7-17, 2004